MITOCHONDRIA AS A TARGET FOR COMBINATION CANCER-CHEMOTHERAPY
Affiliations: MCMASTER UNIV,HAMILTON REG CANC CTR,ONTARIO CANC FDN,HAMILTON L8N 3Z5,ONTARIO,CANADA.
- Published online on: December 1, 1992 https://doi.org/10.3892/ijo.1.7.825
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The purpose of this study was to examine whether mitochondria could be used as a potential target for combination cancer chemotherapy. Mitochondrial specific agents, namely Dequalinium chloride and Rhodamine 123 were tested as single agent and in combination with cis-diammine dichloroplatinum (II). Combination of either cis-diammine dichloroplatinum (II) and Rhodamine 123 or cis-diammine dichloroplatinum (II) and Dequalinium chloride showed that there was a synergistic action. However, combination of Rhodamine 123 and Dequalinium chloride showed a slight antagonistic activity which could be due to competition for the same site. The data also show that a much lower dose of cisplatin is required to produce an equieffective-response when used in combination with Dequalinium chloride and thus may lower the cis-diammine dichloroplatinum (II) induced toxicities.